A treat-to-target approach for obesity management: A post hoc analysis of the SURMOUNT-5 trial.

le Roux CW, Busetto L, Aronne L, Horn DB, Dimitriadis GK, Falcon B, Garcia-Perez LE, Valderas EG, Gibble TH, Senyucel C, Dunn JP

Diabetes, obesity & metabolism3 Feb 2026Cited by 3 (Europe PMC)

PMID41635114PMCIDPMC12992187DOI10.1111/dom.70531PepBankPUB-41635114

Read at source PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

2 results from studies that gave the peptide. 2 results from people.

01HumanObservational studyEfficacy outcome
In adults with obesity in SURMOUNT-5, 23.1%-33.9% of those treated with tirzepatide reached the proposed treat-to-target thresholds for waist to height ratio or BMI.
In plain wordsIn adults with obesity, about a quarter to a third of those given tirzepatide reached the proposed treat-to-target body measure goals.
Peptide
Tirzepatide
Outcome
Not applicableProportion reaching treat-to-target thresholds
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 72 weeksAs given in this study (human).
Measurements
Proportion reaching TtT thresholds
23.1 to 33.9%
tirzepatide
Source sentences
Summary
About 23.1%-33.9% of participants treated with tirzepatide and 14.2%-20.7% treated with semaglutide reached the TtT thresholds
Report a problemFND-4163511401
02HumanObservational studyEfficacy outcome
In adults with obesity in SURMOUNT-5, 14.2%-20.7% of those treated with semaglutide reached the proposed treat-to-target thresholds for waist to height ratio or BMI.
In plain wordsIn adults with obesity, about one in seven to one in five of those given semaglutide reached the proposed treat-to-target body measure goals.
Peptide
Semaglutide
Outcome
Not applicableProportion reaching treat-to-target thresholds
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 72 weeksAs given in this study (human).
Measurements
Proportion reaching TtT thresholds
14.2 to 20.7%
semaglutide
Source sentences
Summary
14.2%-20.7% treated with semaglutide reached the TtT thresholds
Report a problemFND-4163511402

Studies that did not test the peptide alone4

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

03HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In SURMOUNT-5 participants, those who reached WHtR <0.53 more often achieved low disease activity to remission (about 77%; odds ratio 2.31) than those who did not; the result is not split by drug.
In plain wordsIn adults with obesity given tirzepatide or semaglutide, reaching the waist to height goal went with more cases of low disease activity.
Peptide
Tirzepatide
Outcome
Not applicableLow disease activity to remission by WHtR threshold
Study
n: not reported in source
Outcome group
Cardiometabolic risk factors · Metabolic and weight
Measurements
Achieved low disease activity to remission
77%
reached WHtR <0.53
OR
2.31 ratio
reached versus did not reach WHtR <0.53
Source sentences
Summary
About 77% of participants who reached WHtR <0.53 achieved low disease activity to remission, with an odds ratio of 2.31 (p < 0.001) compared to those who did not reach this target.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4163511403
04HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In SURMOUNT-5 participants, those who reached WHtR <0.53 more often achieved low disease activity to remission (about 77%; odds ratio 2.31) than those who did not; the result is not split by drug.
In plain wordsIn adults with obesity given tirzepatide or semaglutide, reaching the waist to height goal went with more cases of low disease activity.
Peptide
Semaglutide
Outcome
Not applicableLow disease activity to remission by WHtR threshold
Study
n: not reported in source
Outcome group
Cardiometabolic risk factors · Metabolic and weight
Measurements
Achieved low disease activity to remission
77%
reached WHtR <0.53
OR
2.31 ratio
reached versus did not reach WHtR <0.53
Source sentences
Summary
About 77% of participants who reached WHtR <0.53 achieved low disease activity to remission, with an odds ratio of 2.31 (p < 0.001) compared to those who did not reach this target.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4163511404
05HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In SURMOUNT-5 participants, reaching the BMI threshold was not statistically associated with SF-36v2 PCS outcomes; the result is not split by drug.
In plain wordsIn adults with obesity given tirzepatide or semaglutide, reaching the BMI goal was not linked to better physical function scores.
Peptide
Tirzepatide
Outcome
No significant changeBMI threshold and SF-36v2 physical component score
Study
n: not reported in source
Outcome group
Exercise and physical function · Metabolic and weight
Source sentences
Summary
The BMI threshold was not statistically associated with the assessed outcomes for SF-36v2 PCS.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4163511405
06HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In SURMOUNT-5 participants, reaching the BMI threshold was not statistically associated with SF-36v2 PCS outcomes; the result is not split by drug.
In plain wordsIn adults with obesity given tirzepatide or semaglutide, reaching the BMI goal was not linked to better physical function scores.
Peptide
Semaglutide
Outcome
No significant changeBMI threshold and SF-36v2 physical component score
Study
n: not reported in source
Outcome group
Exercise and physical function · Metabolic and weight
Source sentences
Summary
The BMI threshold was not statistically associated with the assessed outcomes for SF-36v2 PCS.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4163511406

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 2
9 Oct 2026, 03:07 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.